AU2137595A - Use of arylpiperazine derivatives for the treatment of Parkinson's disease and psychosis - Google Patents

Use of arylpiperazine derivatives for the treatment of Parkinson's disease and psychosis

Info

Publication number
AU2137595A
AU2137595A AU21375/95A AU2137595A AU2137595A AU 2137595 A AU2137595 A AU 2137595A AU 21375/95 A AU21375/95 A AU 21375/95A AU 2137595 A AU2137595 A AU 2137595A AU 2137595 A AU2137595 A AU 2137595A
Authority
AU
Australia
Prior art keywords
psychosis
parkinson
disease
treatment
arylpiperazine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21375/95A
Inventor
David John Heal
Patricia Lesley Needham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Boots Co PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA, Boots Co PLC filed Critical Laboratorios del Dr Esteve SA
Publication of AU2137595A publication Critical patent/AU2137595A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU21375/95A 1994-04-23 1995-03-30 Use of arylpiperazine derivatives for the treatment of Parkinson's disease and psychosis Abandoned AU2137595A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9408084A GB9408084D0 (en) 1994-04-23 1994-04-23 Medical treatment
GB9408084 1994-04-23
PCT/EP1995/001195 WO1995028933A1 (en) 1994-04-23 1995-03-30 Use of arylpiperazine derivatives for the treatment of parkinson's disease and psychosis

Publications (1)

Publication Number Publication Date
AU2137595A true AU2137595A (en) 1995-11-16

Family

ID=10754011

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21375/95A Abandoned AU2137595A (en) 1994-04-23 1995-03-30 Use of arylpiperazine derivatives for the treatment of Parkinson's disease and psychosis

Country Status (5)

Country Link
AU (1) AU2137595A (en)
ES (1) ES2116880B1 (en)
GB (1) GB9408084D0 (en)
WO (1) WO1995028933A1 (en)
ZA (1) ZA953237B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633377A (en) * 1990-12-28 1997-05-27 Neurogen Corporation 4-piperidino- and piperazinomethyl-2-cyclohexyl imidazole derivatives; dopamine receptor subtype specific ligands
US6166205A (en) * 1998-09-02 2000-12-26 Neurogen Corporation 2-Aryl-4-(1-[4-heteroaryl]piperazin-1-yl)methylimidazoles: dopamine . D.sub4 receptor subtype ligands
HN1999000146A (en) 1998-09-21 2000-11-11 Pfizer Prod Inc PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PARKINSON'S DISEASE, ADHD AND MICROADENOMAS.
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2671972B1 (en) * 1991-01-25 1995-03-03 Esteve Labor Dr USE OF 1-H-AZOLE- (OMEGA- (4- (2-PYRIMIDINYL) -1-PIPERAZINYL) -ALKYL) DERIVATIVES FOR THE PREPARATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF COGNITIVE FUNCTION DISORDERS.

Also Published As

Publication number Publication date
WO1995028933A1 (en) 1995-11-02
GB9408084D0 (en) 1994-06-15
ES2116880A1 (en) 1998-07-16
ES2116880B1 (en) 1999-08-01
ZA953237B (en) 1995-12-28

Similar Documents

Publication Publication Date Title
AU6974996A (en) Compositions for the treatment of dermatological disorders and methods for their use
AU2209697A (en) Fluorocarbons for diagnosis and treatment of articular disorders
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
AU5772196A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU5772296A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
EP0331620A3 (en) Agent for the treatment of parkinson's disease
AP2001002102A0 (en) Pharmaceutical agents for the treatment of parkinson's disease and adhd and microadenomas
AU5772396A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU2466695A (en) The use of famotidine and related compounds in the treatment of movement disorders
EP1011644A4 (en) Methods and apparatus for treatment of parkinson's disease
AU4018897A (en) Novel 3,4-diaryloxazolone derivatives, methods of preparation and therapeutic uses thereof
HUP9901176A3 (en) Process for the preparation of 2,2'-bipyrrolyl-pyrromethene (prodigiosins) derivatives and their intermediates
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
AU5053296A (en) Pharmaceutical agents for the treatment of Alzheimer's disease
AU2137595A (en) Use of arylpiperazine derivatives for the treatment of Parkinson's disease and psychosis
AU1807592A (en) New combination preparation for treatment of parkinson's disease
AU4841296A (en) Diagnosis of and compositions and methods for the treatment of disease
IL117191A0 (en) Process for the preparation of oxazolidinones and their use
AU7622798A (en) Application of thalidomide to the treatment of Parkinson's disease and Parkisonian syndromes
AU8195091A (en) Ropinirole and domperidone for use in the manufacture of a medicament for the treatment of parkinson's disease
EP0862442A4 (en) Methods for diagnosis and treatment of bloom's syndrome
AU6955294A (en) Agents for the prevention and treatment of parkinson's disease
AU1801297A (en) Spiro-ketal derivatives and their use as therapeutic agents
HUP9800272A3 (en) Use of penciclovir for the treatment of human herpes-virus-8